AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $64.53
- 52-wk high
- $68.64
- High
- $65.04
- 52-wk low
- $41.13
- Low
- $64.26
- Prev close
- $64.69
- Mkt cap
- $130.00B
- P/E
- 14.0x
- Volume
- 6.57M
- Fwd P/E
- 9.9x
- Beta
- 0.23
- Div yield
- 3.94%
- P/S
- 2.6x
- P/B
- 5.9x
- Profit margin
- +18.9%
- Op margin
- +34.4%
- ROE
- +46.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 28.3% above what analysts expected.
Earnings per share
$1.59 expected
Reports Oct 29, 2026, in 46 days
EPS expected
$1.59 to $1.92
Revenue expected
18 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Cost of what it sold | $3.44B | $4.10B | $3.42B | $3.73B |
| Gross profit | $8.79B | $8.41B | $8.07B | $9.25B |
| What it spent | ||||
| Research and development | $2.53B | $2.59B | $2.65B | $2.96B |
| Sales and admin | $1.79B | $2.18B | $1.62B | $1.83B |
| Other operating costs | $831.0M | $826.0M | $437.0M | $376.0M |
| Total operating expenses | $5.15B | $5.59B | $4.70B | $5.16B |
| What was left | ||||
| Operating profit | $3.64B | $2.81B | $3.37B | $4.09B |
| Interest on debt | $480.0M | $432.0M | $411.0M | $407.0M |
| Profit before tax | $3.11B | $1.47B | $3.24B | $4.09B |
| Tax | $919.0M | $384.0M | $561.0M | $770.0M |
| Net profit | $2.20B | $1.09B | $2.68B | $3.32B |
| EBITDA | $4.61B | $2.88B | $4.25B | $4.94B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock
Leans bearishSep 11Incyte at Cantor conference: pipeline advances, post-Jakafi plan By Investing.com
NeutralSep 10National Pension Service Acquires 46,936 Shares of Bristol Myers Squibb Company $BMY
Leans bullishSep 10Allworth Financial LP Sells 91,375 Shares of Bristol Myers Squibb Company $BMY
NeutralSep 10Alumis at Cantor conference: psoriasis strength, lupus setback
NeutralSep 10VTRS - Viatris Inc Volatility & Greeks
NeutralSep 9Humana sues Bayer over unpaid medical liens in Roundup settlements
Leans bearishSep 9Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc.
NeutralSep 9
Macro
21 macro signals shaping BMY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results